Delving into the Latest Updates on SAR-502250 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

glycogen synthase kinase 3beta inihibitors (Mitsubish Tanabe)

Target

GSK-3β x Tau tubulin kinase (TTBK) family

Action

inhibitors

Mechanism

GSK-3β inhibitors(Glycogen synthase kinase-3 beta inhibitors), Tau tubulin kinase (TTBK) family inhibitors

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication-

Inactive Indication

Alzheimer DiseaseDiabetes Mellitus, Type 2Schizophrenia

Originator Organization

Sanofi SA

Active Organization-

Inactive Organization

Mitsubishi Pharma Corp.

Sanofi SA

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

AbstractGlycogen synthase kinase 3 (GSK3) has been identified as a promising target for the treatment of Alzheimer’s disease (AD), where abnormal activation of this enzyme has been associated with hyperphosphorylation of tau proteins. This study describes the effects of the selective GSK3 inhibitor, SAR502250, in models of neuroprotection and neuropsychiatric symptoms (NPS) associated with AD. In P301L human tau transgenic mice, SAR502250 attenuated tau hyperphosphorylation in the cortex and spinal cord. SAR502250 prevented the increase in neuronal cell death in rat embryonic hippocampal neurons following application of the neurotoxic peptide, Aβ25–35. In behavioral studies, SAR502250 improved the cognitive deficit in aged transgenic APP(SW)/Tau(VLW) mice or in adult mice after infusion of Aβ25–35. It attenuated aggression in the mouse defense test battery and improved depressive-like state of mice in the chronic mild stress procedure after 4 weeks of treatment. Moreover, SAR502250 decreased hyperactivity produced by psychostimulants. In contrast, the drug failed to modify anxiety-related behaviors or sensorimotor gating deficit. This profile confirms the neuroprotective effects of GSK3 inhibitors and suggests an additional potential in the treatment of some NPS associated with AD.

100 Deals associated with SAR-502250

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Discovery	France	Sanofi SA	-
Diabetes Mellitus, Type 2	Discovery	France	Sanofi SA	-
Diabetes Mellitus, Type 2	Discovery	Japan	Mitsubishi Pharma Corp.	-
Schizophrenia	Discovery	France	Sanofi SA	-
Schizophrenia	Discovery	Japan	Mitsubishi Pharma Corp.	-